Abstract | AIM: MATERIALS AND METHODS: Inpatients with non-affective catatonia (n= 18) non-responsive to at least five-day trial of lorazepam (6-8 mg/day) were randomised into two groups in a double blind randomised design. Written informed consent was obtained. Four were dropped from the trial as they were found to have depressive catatonia. One group received true ECT (thrice weekly, n=8) plus oral placebo while the other received sham ECT plus risperidone (4-6 mg/ day). Bush-Francis Catatonia Rating Scale (BFCRS) was administered twice weekly to assess improvement in catatonic symptoms over a period of three weeks. The two groups were compared using two-way RMANOVA. RESULTS: BFCRS scores reduced markedly over treatment course and this reduction was more profound in the ECT group (p=0.035). Shorter the duration of illness greater was the response (lower scores of BFCRS). CONCLUSIONS: Superior clinical efficacy of ECT over neuroleptics in catatonia is confirmed by this randomized clinical trial.
|
Authors | K Girish, Neeraj S Gill |
Journal | Indian journal of psychiatry
(Indian J Psychiatry)
Vol. 45
Issue 1
Pg. 21-5
(Jan 2003)
ISSN: 0019-5545 [Print] India |
PMID | 21206808
(Publication Type: Journal Article)
|